{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:15:53Z","timestamp":1757704553373,"version":"3.40.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00198-020-05722-4","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T14:02:50Z","timestamp":1604498570000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-2637","authenticated-orcid":false,"given":"H.R.","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-614X","authenticated-orcid":false,"given":"A.","family":"Nune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Venkatachalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"issue":"suppl 1","key":"5722_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis -2020 update. Endo Pract 26(suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endo Pract"},{"key":"5722_CR2","unstructured":"National Health Service (NHS), England. Monthly diagnostic waiting times. Available at: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/diagnostics-waiting-times-and-activity\/monthly-diagnostics-waiting-times-and-activity\/monthly-diagnostics-data-2020-21\/"},{"key":"5722_CR3","unstructured":"The Royal College of Radiologists (2020) COVID-19 interim guidance on restarting elective work. Available at https:\/\/www.rcr.ac.uk\/sites\/default\/files\/covid-19-interim-recovery-guidance.pdf [Accessed 22\/06\/2020]"},{"key":"5722_CR4","unstructured":"Royal Osteoporosis Society (2020) DXA restoration of service toolkit. Available at https:\/\/analytics-eu.clickdimensions.com\/therosorguk-ab8h4\/pages\/c98328b1e0afea11a812000d3a86d7a3.html [Accessed 23\/06\/2020]"},{"key":"5722_CR5","unstructured":"FRAX\u00ae Fracture Risk Assessment Tool (2008) University of Sheffield, UK. Available at: https:\/\/www.sheffield.ac.uk\/FRAX\/ [ accessed 21\/06\/2020]"},{"key":"5722_CR6","doi-asserted-by":"publisher","unstructured":"Kanis J, Cooper C, Rizzoli R et al (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","DOI":"10.1007\/s00198-018-4704-5"},{"key":"5722_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor- associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"issue":"Suppl 1","key":"5722_CR8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(Suppl 1):S3\u2013S18. https:\/\/doi.org\/10.1016\/j.ctrv.2008.03.007","journal-title":"Cancer Treat Rev"},{"key":"5722_CR9","doi-asserted-by":"publisher","first-page":"e000014","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot K, Roux C (2015) Glucocorticoid-induced osteoporosis. RMD Open. 1:e000014. https:\/\/doi.org\/10.1136\/rmdopen-2014-000014","journal-title":"RMD Open."},{"issue":"3","key":"5722_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"J Kanis","year":"2011","unstructured":"Kanis J, Johansson H, Oden A, McCloskey E (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 22(3):809\u2013816. https:\/\/doi.org\/10.1007\/s00198-010-1524-7","journal-title":"Osteoporosis Int."},{"issue":"1","key":"5722_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1):7\u201316. https:\/\/doi.org\/10.1007\/s12020-018-1588-2","journal-title":"Endocrine"},{"key":"5722_CR12","unstructured":"National Osteoporosis Society Guidelines group (NOGG) (2017) available at: https:\/\/www.sheffield.ac.uk\/NOGG\/mainrecommendations.html [Accessed 21\/06\/2020]"},{"issue":"8","key":"5722_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink H et al (2017) American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Rheumatol. 2017 Nov;69(11):2246]. Arthritis Rheumatol 69(8):1521\u20131537. https:\/\/doi.org\/10.1002\/art.40137","journal-title":"Arthritis Rheumatol"},{"key":"5722_CR14","unstructured":"UK Government. Clinically extremely vulnerable groups Available at: https:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19. [Accessed 25\/06\/2020]"},{"issue":"4","key":"5722_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.carj.2011.05.001","volume":"62","author":"B Lentle","year":"2011","unstructured":"Lentle B, Cheung AM, Hanley DA et al (2011) Osteoporosis Canada 2010 guidelines for the assessment of fracture risk [published correction appears in Can Assoc Radiol J. 2012 May; 63(2):78]. Can Assoc Radiol J 62(4):243\u2013250. https:\/\/doi.org\/10.1016\/j.carj.2011.05.001","journal-title":"Can Assoc Radiol J"},{"key":"5722_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsdottir K, Oden A et al (2017) Imminent risk for fracture after fracture. Osteoporosis Int. 28:775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporosis Int."},{"key":"5722_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"J Kanis","year":"2020","unstructured":"Kanis J, Harvey N, McCloskey E et al (2020) Algorithm for the management of patient at low, high and very high risk of osteoporotic fractures. Osteoporosis Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporosis Int"},{"key":"5722_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-020-05517-7","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Johansson H, Harvey NC et al (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporosis Int 31:1817\u20131828. https:\/\/doi.org\/10.1007\/s00198-020-05517-7","journal-title":"Osteoporosis Int"},{"issue":"5","key":"5722_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4236\/health.2015.75061","volume":"7","author":"J Sale","year":"2015","unstructured":"Sale J, Jain R, Akilan K et al (2015) What do we know about individuals who are assessed as being at moderate risk for future fracture in Canada? Health (Irvine Calif) 7(5):514\u2013520. https:\/\/doi.org\/10.4236\/health.2015.75061","journal-title":"Health (Irvine Calif)"},{"key":"5722_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2036.2010.04554.x","volume":"33","author":"J Goodhand","year":"2011","unstructured":"Goodhand J, Kamperidis N, Nguyen H et al (2011) Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 33:551\u2013558. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04554.x","journal-title":"Aliment Pharmacol Ther"},{"key":"5722_CR21","doi-asserted-by":"publisher","unstructured":"Gittoes NJ, Criseno S, Appelman-Dijkstra NM et al (2020) Endocrinology in the time of COVID-19: management of calcium disorders and osteoporosis. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-20-0385 EJE-20-0385. [published online ahead of print, 2020 May 1]","DOI":"10.1530\/EJE-20-0385"},{"key":"5722_CR22","unstructured":"The International Society for Clinical Densitometry (ISCD) (2020) COVID-19 DXA guidance. Available at https:\/\/www.iscd.org\/about-iscd\/iscd-covid-19-dxa-guidance\/ [Accessed 19\/06\/2020]"},{"issue":"6","key":"5722_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jbmr.4049","volume":"35","author":"E Yu","year":"2020","unstructured":"Yu E, Tsourdi E, Clarke B et al (2020) Osteoporosis management in the era of COVID-19. J Bone Miner Res. 35(6):1009\u20131013. https:\/\/doi.org\/10.1002\/jbmr.4049","journal-title":"J Bone Miner Res."},{"issue":"10001","key":"5722_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353\u20131361. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4 Erratum in: Lancet. 2016 Jan 2;387(10013):30. Erratum in: Lancet. 2017 Jun 24;389(10088):2472","journal-title":"Lancet"},{"issue":"3","key":"5722_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger G et al (2019) Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):339\u2013351. https:\/\/doi.org\/10.1016\/S1470-2045(18)30862-3","journal-title":"Lancet Oncol"},{"issue":"15","key":"5722_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"K Saag","year":"2017","unstructured":"Saag K, Petersen J, Brandi M et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med."},{"issue":"10117","key":"5722_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"D Kendler","year":"2018","unstructured":"Kendler D, Marin F, Zerbini C et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05722-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-020-05722-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05722-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T16:21:26Z","timestamp":1608654086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-020-05722-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5722"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05722-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}